Trials
Search / Trial NCT05640531

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

Launched by WOCKHARDT · Nov 28, 2022

Trial Information

Current as of January 14, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Have a Body Mass Index (BMI) between 18 and 32 (both inclusive), calculated as weight in kg/height in m2
  • Have no significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations and ECG recordings
  • Exclusion Criteria:
  • Known hypersensitivity or idiosyncratic reaction to quinolones or any other related drugs
  • Any history or evidence of disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system
  • Use of any prescription drug within 14 days prior to start of the study (check-in) and nonprescription drug within 7 days prior to start of study (check-in)

Trial Officials

Ashima Bhatia, MD

Study Director

Wockhardt Ltd

About Wockhardt

Wockhardt is a global pharmaceutical and biotechnology company headquartered in India, renowned for its innovative research and development in the fields of human health and biopharmaceuticals. With a focus on delivering high-quality, affordable medications, Wockhardt specializes in a wide range of therapeutic areas, including antibiotics, vaccines, and biotechnology-derived products. The company is committed to advancing medical science through rigorous clinical trials, ensuring the efficacy and safety of its products while adhering to the highest regulatory standards. Wockhardt's dedication to improving patient outcomes and enhancing healthcare accessibility positions it as a key player in the global pharmaceutical landscape.

Locations

Austin, Texas, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials